Abstract
T he density of the breast parenchyma generally decreases as women approach and go through menopause. Hormone replacement therapy frequently slows and in many women reverses this phenomenon [I, 2]. Such an increase in parenchymal density is usually generalized but may be focal, mimicking a suspicious process. In the latter situation, we have occasionally used short-interval followup (2-3 months) after withdrawal of estrogen therapy. If caused by estrogen, the abnormality will typically regress, confirming its relationship to estrogen replacement therapy (Fig. 1). We have recently seen a woman with a nonpalpable malignant lesion that shrank considerably in the S weeks after cessation of hormone replacement therapy and proved to be a malignant breast carcinoma after surgical excision.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
